Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Endocrinol Metab (Seoul). 2015 Sep;30(3):252-62. doi: 10.3803/EnM.2015.30.3.252.
Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase pathway. B-Raf proto-oncogene (BRAF) mutations are the most common mutations observed in papillary thyroid cancers (PTCs), followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements. Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter have recently been associated with clinicopathologic features, disease prognosis, and tumorigenesis in thyroid cancer. While the mutations underlying thyroid tumorigenesis are well known, the frequency of these mutations is strongly associated with geography, with clear differences reported between Asian and Western countries. Of particular interest is the prevalence of BRAF mutations, with Korean patients exhibiting the highest rate of BRAF-associated thyroid cancers in the world. Here, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer in Asians.
近年来,分子诊断学的进展使得人们对甲状腺肿瘤发生的遗传基础有了更深入的了解。在甲状腺癌中常见的突变中,绝大多数与丝裂原活化蛋白激酶途径有关。B-Raf 原癌基因(BRAF)突变是最常见的在甲状腺乳头状癌(PTC)中观察到的突变,其次是 RET/PTC 重排和 RAS 突变,而滤泡性甲状腺癌更可能携带 RAS 突变或 PAX8/过氧化物酶体增殖物激活受体 γ(PPARγ)重排。除了这些更常见的突变外,端粒酶逆转录酶(TERT)启动子的改变最近与甲状腺癌的临床病理特征、疾病预后和肿瘤发生有关。虽然导致甲状腺肿瘤发生的突变是众所周知的,但这些突变的频率与地理位置密切相关,亚洲和西方国家之间存在明显差异。特别值得关注的是 BRAF 突变的流行率,韩国患者的 BRAF 相关甲状腺癌发生率居世界首位。在这里,我们回顾了亚洲和西方国家最常见的每种突变的流行率,并确定了亚洲人分化型甲状腺癌的特征。